ReviewJournal of immunology research2025
Follicular Helper T Cells: Potential Interventional Targets in Atherosclerosis.
Review in Journal of immunology research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Follicular Helper T Cells: Potential Interventional Targets in Atherosclerosis.Journal of immunology research · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atherosclerosis (AS) is a disease characterized by the presence of lesions in the arterial intima throughout the circulatory system. Lipid metabolism disorders form the pathological basis of AS. Immune injury resulting from lipid deposition, which is regulated by various cytokines, significantly contributes to disease progression. Follicular helper T (Tfh) cells are essential in the humoral immune response. The abnormal expression of surface molecules and cytokines by Tfh cells may contribute to the onset and progression of AS. Additionally, an increase in the Tfh cell population contributes to the progression of AS and coronary artery disease (CAD). Therefore, the targeting of Tfh cells and their associated functional molecules could serve as a promising therapeutic strategy against AS. This review summarizes current insights into the role of Tfh cells in AS and highlights their potential as therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.